Comparison of effect and quality of life of docetaxel and erlotinib in treatment with non-small cell lung cancer who failed first line chemotherapy
HAO Wei
SONG Chunqing
LU Guilong
XUN Pei
LU Yuanli
HAN Lei
Abstract：Objective To compare the clinical efficacy and safety of erlotinib and docetaxel in patients with advanced non-small cell lung cancer ( NSCLC) with the first-line chemotherapy failure, and assess quality of life. Methods 78 cases of NSCLC patients with first-line chemotherapy failure were enrolled, according to the random number table method, they were divided into 2 groups, using docetaxel (docetaxel group, n =39) 75 mg/m2 intravenous infusion of 2 h, every 21 days;erlo-tinib (erlotinib group, n =39) 150 mg orally, once daily. The objective relieve rate (ORR), disease control rate (DCR), Karnofsky score, progression free survival ( PFS) and adverse reactions were compared between the 2 groups. Results Erlo-tinib group’ s ORR and DCR were significantly higher than those in docetaxel group (28. 2% vs. 10. 3%, 61. 5% vs. 38. 5%, P <0. 05);compared with docetaxel group, erlotinib group rash degree increased significantly, platelet count were decreased and liver function abnormalities were ameliorated ( P <0. 05 ); after chemotherapy, Karnofsky scores of the 2 groups were significantly increased ( t =7. 16, t =5. 00, P <0. 05), and erlotinib group was significantly higher than that of the docetaxel group ( t =3. 81, P <0. 05). Erlotinib group had a median PFS of 7. 73 months (95% CI 7. 51-7. 90), do-cetaxel group had a median PFS of 7. 30 months (95% CI 7. 08-7. 52) and erlotinib group’ s median PFS was longer than docetaxel group (χ2 =5. 80, P <0. 05). Conclusion Erlotinib targeted treatment can improve clinical effects of advanced NSCLC, safety and tolerability are better, and it can improve the quality of life of patients and prolong survival time.
Keywords：Non-small cell lung cancerDocetaxelErlotinibTargeted therapy
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 775-777,781 )